SAN DIEGO, Sept. 1, 2016 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), an oncology biotech developing
novel oncology and drug-delivery therapies, today named biotech
veteran Mark J. Gergen as senior
vice president and chief operating officer, reporting to Dr.
Helen Torley, president and chief
executive officer.
Gergen will be responsible for corporate development,
including the management of Halozyme's proprietary ENHANZE™
platform collaborations and overseeing the global product teams
responsible for planning the development and commercialization of
Halozyme's oncology pipeline, including clinical operations and
clinical collaborations.
"Mark brings a wealth of business development and operational
experience that will be essential as we execute our plan to
accelerate growth of the ENHANZE platform and develop and
commercialize multiple oncology drugs," said Dr. Torley. "With more
than 20 years of healthcare and biotech experience, he will be a
strong addition to our management team as we execute our growth
strategy."
Gergen joins Halozyme most recently from Mirati Therapeutics, an
oncology biotech, where he was executive vice president and chief
operating officer reporting to the CEO and responsible for the
strategy, corporate development, finance, investor relations, human
resources, information technology and legal functions. He executed
multiple successful partnerships, collaborations and licensing
agreements.
Before Mirati, he spent 7 years at Amylin Pharmaceuticals as a
member of the executive committee reporting to the CEO, where he
led corporate development and alliances.
"I am excited to join the Halozyme team as the company continues
to execute against its business objectives and corporate strategy,"
said Gergen. "The advancements in the oncology pipeline together
with the opportunity to grow the proprietary ENHANZE platform
create a unique opportunity to build significant shareholder
value."
Prior to Amylin, Gergen held senior management roles for
Cardionet and Advanced Tissue Sciences, as well as the large group
purchasing organization, Premier, and medical device pioneer,
Medtronic. He earned his B.A. in Business Administration from
Minot State University in North Dakota and J.D. from the University of Minnesota Law School.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on
developing and commercializing novel oncology therapies that target
the tumor microenvironment. Halozyme's lead proprietary program,
investigational drug PEGPH20, applies a unique approach to
targeting solid tumors, allowing increased access of
co-administered cancer drug therapies to the tumor in animal
models. PEGPH20 is currently in development for metastatic
pancreatic cancer, non-small cell lung cancer, gastric cancer,
metastatic breast cancer and has potential across additional
cancers in combination with different types of cancer therapies. In
addition to its proprietary product portfolio, Halozyme has
established value-driving partnerships with leading pharmaceutical
companies including Roche, Baxalta, Pfizer, Janssen, AbbVie and
Lilly for its ENHANZE™ drug delivery platform. Halozyme is
headquartered in San Diego. For
more information visit www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth
above include forward-looking statements (including, without
limitation, statements concerning the Company's future expectations
and plans for growth, future execution of the Company's business
strategy, the development and commercialization of product
candidates and the potential benefits and attributes of such
product candidates, future prospects of the Company's ENHANZE
platform and increasing the number of strategic partners) that
involve risk and uncertainties that could cause actual results to
differ materially from those in the forward-looking statements. The
forward-looking statements are typically, but not always,
identified through use of the words "believe," "enable," "may,"
"will," "could," "intends," "estimate," "anticipate," "plan,"
"predict," "probable," "potential," "possible," "should,"
"continue," and other words of similar meaning. Actual results
could differ materially from the expectations contained in
forward-looking statements as a result of several factors,
including unexpected results in executing the Company's business
strategy including its efforts to grow the ENHANZE platform,
unexpected expenditures and costs, unexpected fluctuations or
changes in revenues, including revenues from collaborators,
unexpected results or delays in development of product candidates
and regulatory review, regulatory approval requirements, the
Company's efforts to increase the number of strategic partners not
producing expected results, unexpected adverse events and
competitive conditions. These and other factors that may result in
differences are discussed in greater detail in the Company's most
recent Annual and Quarterly Reports filed with the Securities and
Exchange Commission.
Contacts:
Jim
Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-names-mark-j-gergen-as-chief-operating-officer-300321226.html
SOURCE Halozyme Therapeutics, Inc.